Top Key Companies for Cancer Microbiome Testing Market: CD Genomics, Eurofins Scientific, Illumina, Prescient Medicine Holding, Micronoma, Novogene, Oxford Nanopore Technologies, Pacific Biosciences, Qiagen, Therma Fisher Scientific.
Global Cancer Microbiome Testing Market Size was estimated at USD 182.92 million in 2022 and is projected to reach USD 221.36 million by 2028, exhibiting a CAGR of 3.23% during the forecast period.
Global Cancer Microbiome Testing Market Overview And Scope:
The Global Cancer Microbiome Testing Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Cancer Microbiome Testing utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
This Market Research Report provides a comprehensive analysis of the global Cancer Microbiome Testing Market and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Microbiome Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cancer Microbiome Testing market.
Global Cancer Microbiome Testing Market Segmentation
By Type, Cancer Microbiome Testing market has been segmented into:
Next Generation Sequencing
Polymerase Chain Reaction
By Application, Cancer Microbiome Testing market has been segmented into:
Hospitals
Clinic
Others
Regional Analysis of Cancer Microbiome Testing Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Cancer Microbiome Testing Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Cancer Microbiome Testing market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Cancer Microbiome Testing market.
Top Key Companies Covered in Cancer Microbiome Testing market are:
CD Genomics
Eurofins Scientific
Illumina
Prescient Medicine Holding
Micronoma
Novogene
Oxford Nanopore Technologies
Pacific Biosciences
Qiagen
Therma Fisher Scientific
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Cancer Microbiome Testing Market by Type
5.1 Cancer Microbiome Testing Market Overview Snapshot and Growth Engine
5.2 Cancer Microbiome Testing Market Overview
5.3 Next Generation Sequencing
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Next Generation Sequencing: Geographic Segmentation
5.4 Polymerase Chain Reaction
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Polymerase Chain Reaction: Geographic Segmentation
Chapter 6: Cancer Microbiome Testing Market by Application
6.1 Cancer Microbiome Testing Market Overview Snapshot and Growth Engine
6.2 Cancer Microbiome Testing Market Overview
6.3 Hospitals
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospitals: Geographic Segmentation
6.4 Clinic
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Clinic: Geographic Segmentation
6.5 Others
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Cancer Microbiome Testing Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Cancer Microbiome Testing Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Cancer Microbiome Testing Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 CD GENOMICS
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 EUROFINS SCIENTIFIC
7.4 ILLUMINA
7.5 PRESCIENT MEDICINE HOLDING
7.6 MICRONOMA
7.7 NOVOGENE
7.8 OXFORD NANOPORE TECHNOLOGIES
7.9 PACIFIC BIOSCIENCES
7.10 QIAGEN
7.11 THERMA FISHER SCIENTIFIC
Chapter 8: Global Cancer Microbiome Testing Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Next Generation Sequencing
8.2.2 Polymerase Chain Reaction
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospitals
8.3.2 Clinic
8.3.3 Others
Chapter 9: North America Cancer Microbiome Testing Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Next Generation Sequencing
9.4.2 Polymerase Chain Reaction
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospitals
9.5.2 Clinic
9.5.3 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Cancer Microbiome Testing Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Next Generation Sequencing
10.4.2 Polymerase Chain Reaction
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospitals
10.5.2 Clinic
10.5.3 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Cancer Microbiome Testing Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Next Generation Sequencing
11.4.2 Polymerase Chain Reaction
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospitals
11.5.2 Clinic
11.5.3 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Cancer Microbiome Testing Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Next Generation Sequencing
12.4.2 Polymerase Chain Reaction
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospitals
12.5.2 Clinic
12.5.3 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Cancer Microbiome Testing Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Next Generation Sequencing
13.4.2 Polymerase Chain Reaction
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospitals
13.5.2 Clinic
13.5.3 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Cancer Microbiome Testing Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Next Generation Sequencing
14.4.2 Polymerase Chain Reaction
14.5 Historic and Forecasted Market Size By Application
14.5.1 Hospitals
14.5.2 Clinic
14.5.3 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Cancer Microbiome Testing Scope:
|
Report Data
|
Cancer Microbiome Testing Market
|
|
Cancer Microbiome Testing Market Size in 2025
|
USD XX million
|
|
Cancer Microbiome Testing CAGR 2025 - 2032
|
XX%
|
|
Cancer Microbiome Testing Base Year
|
2024
|
|
Cancer Microbiome Testing Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
CD Genomics, Eurofins Scientific, Illumina, Prescient Medicine Holding, Micronoma, Novogene, Oxford Nanopore Technologies, Pacific Biosciences, Qiagen, Therma Fisher Scientific.
|
|
Key Segments
|
By Type
Next Generation Sequencing
Polymerase Chain Reaction
By Applications
Hospitals
Clinic
Others
|
